Nom du produit:8-Methoxy-2-methyl-4-(1-methyl-1H-1,2,4-triazol-5-yl)quinoline
IUPAC Name:8-methoxy-2-methyl-4-(1-methyl-1H-1,2,4-triazol-5-yl)quinoline
- CAS：2340117-38-4
- Formule moléculaire：C14H14N4O
- Pureté：95%+
- Numéro de catalogue：CM1075078
- Poids moléculaire：254.29
| Unité d'emballage |
Stock disponible |
Prix($) |
Quantité |
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:2340117-38-4
- Formule moléculaire:C14H14N4O
- Point de fusion:-
- Code SMILES:N=1C=NN(C1C=2C=C(N=C3C(OC)=CC=CC32)C)C
- Densité:
- Numéro de catalogue:CM1075078
- Poids moléculaire:254.29
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Quinolines
- Quinolines are an important class of biologically active heterocyclic compounds, and their derivatives usually exhibit a variety of biological activities. They can be used as antimalarial drugs and in the preparation of other antimalarial drugs. Other important activities of quinoline derivatives include inhibitory activity against EGFR-TK and antipsychotic activity. Futhermore, quinoline scaffolds are present in various drug molecules, including the antimalarial drugs aablaquine, chloroquine, mefloquine and primaquine, and the antibacterial agents gatifloxacin, levofloxacin, and moxifloxacin.
- Quinoline Price
- if you have any question on quinoline price, we will give the professional answers to your short questions.
- Triazoles
- Triazole refers to a heterocyclic compound with the molecular formula C2H3N3, which has a five-membered ring consisting of two carbon atoms and three nitrogen atoms. Neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease already affect many people around the world, and these numbers are increasing rapidly. Treatment for these disorders is often aimed at relieving symptoms and has no cure. Research on new molecules is underway, and heterocyclic compounds have important pharmacological implications. Triazoles and tetrazoles are emerging as new molecules in this field.
Column Infos
- Deucrictibant
- Pharvaris announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoint, with deucrictibant demonstrating statistically significant and clinically meaningful results of deucrictibant as an oral preventative treatment for people living with HAE. The study's primary endpoint measured the time-standardized number of investigator-confirmed HAE episodes during treatment. Participants receiving 40 mg of deucrictibant daily had an 84.5% reduction in monthly exacerbation rates compared to placebo (p=0.0008). Deucrictibant is a potent, selective, and orally available antagonist of the bradykinin B2 receptor. By inhibiting bradykinin signaling through the bradykinin B2 receptor, deucrictibant has the potential to treat the clinical signs of an HAE attack and to prevent the occurrence of attacks.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Recherche 
+86 21 5895 0110 
